Objective-To investigate the prevalence of
Introduction
Despite considerable circumstantial evidence that the causal agent in sarcoidosis is likely to be a mycobacterium no conclusive association that might influence treatment has yet been shown. Both are multisystem granulomatous disorders, and patients commonly present with such similar symptoms that sarcoidosis was once held to be a variant form of tuberculosis. In addition to the clinical and histological similarities between the two diseases, there is much evidence from immunological,' 2 epidemiological,34 and microbiological'6 studies to suggest a common cause. Patients, however, still have no specific treatment option and rely on being in the majority of patients who spontaneously recover. For the remainder with pre-fibrotic lung infiltration, about 7% will progress to respiratory failure, right ventricular failure, and death within 10 to 15 years. 7 One reason for the controversy surrounding the association between sarcoidosis and Mycobacterium tuberculosis is the absence of acid fast organisms on routine Ziehl-Neelsen staining of sarcoid tissues. Yet it is now becoming well recognised that pathogens may exist in forms without cell walls and may generate "slow bacterial infections" in which the organism will not be easily cultured.8 The tubercle bacillus has long been recognised to exist in various guises9 and seems able to exist interchangeably with and without its cell wall.'0 When a concerted and invasive effort has been made to find acid fast rods in sarcoid tissue they seem to be present,' and acid fast bacteria without cell walls" and tuberculostearic acid'2 have also been isolated from lesions of patients with sarcoidosis.
With the advent of the ultrasensitive polymerase chain reaction for detecting DNA in clinical samples the opportunity to unravel the debate should be available. The Two sets of primers were used. IS6110 is specific for the M tuberculosis complex and is present in multiple copies in M tuberculosis, in a single copy in M bovis BCG, and in 1-5 copies in M bovis. " It has been validated for early diagnosis of tuberculosis. '3 '9 Primers were designed to amplify a 305 base pair product as INS 1: 5' CGTGAGGGCATCGAGGTGGC 3' and INS 2: 5' GCGTAGGCGTCGGTGACAAA 3'. Primers were made from a section of mycobacterial specific (65 kilodalton gene, TB1 and 2) groEL gene which is conserved among known mycobacteria but not specific for M tuberculosis.'420 They produced a product of 625 base pairs: TB 1: 5' GAGATCGAGCTGGAGGATCCGTACG 3' and TB 2: 5' GCGGATCTTGTTGACGACCAGGG 3'. Amplification was performed as described elsewhere9 but with a 25 p1 reaction volume with 5 p1 of sample added. The amplified products were electrophoresed through a 1-5% agarose gel stained with ethidium bromide and viewed under ultraviolet light. Positive controls of 12-5 fg and 36 fg of M tuberculosis DNA were run respectively for IS6110 and 65 kilodalton primers to reflect their differing sensitivities.
For greater sensitivity we then performed Southern hybridisation and probing. By blotting the gel containing amplified product on to a positively charged nylon membrane and probing (or "hybridising") this with a heterologous labelled strand of DNA the sensitivity of detection can be increased 10-fold.2'22 Thus a gel which appears to contain no product may reveal the presence of 10 fg of mycobacterial DNA, equivalent to less than 2 genomes.'4 This procedure was performed for all specimens and both DNA products. Probes were prepared by random oligonucleotide labelling with digoxigenin of the products of the polymerase chain reaction electrophoresed through a 1-5% agarose gel, excised, and purified with Gene-Clean (Bio 101, La Jolla, California).
STATISTICS
We used double classification X2 testing to assess the significance of the differences in positivity for the patients with sarcoidosis and controls.
Results
The specificity of the polymerase chain reaction primers has previously been validated'4 but the sensitivity was reassessed. We found we could detect 12 10 samples. To detect contamination occurring during preparation of samples, negative control samples containing only water were treated exactly as the tissue samples and examined by polymerase chain reaction techniques. One negative control sampled was processed for every three tissue samples examined.
Despite stringent precautions taken to avoid contamination in some batches of samples processed occasional negative control samples gave positive amplification on the polymerase chain reaction. We also found that, although samples from the same section gave consistently positive or negative amplification, serial sections from the same tissue block sometimes gave discordant results, presumably due to nonuniform distribution of mycobacteria within the tissue block. We therefore applied the following criteria to define a positive result.
Any sample for which a single section gave positive amplification for the IS6110 primers in an experiment in which all negative controls in the batch were negative was recorded as presumptive positive for M tuberculosis complex DNA. Additionally, a presumptive positive result was recorded for any sample if three out offour of the sections examined were positive for the IS61 10 29-67% ." 3 23 The positive controls in our experiment that were negative for the polymerase chain reaction were also culture negative, and our apparent low sensitivity is consistent with previous work on clinical samples."4 This is disappointing for such a theoretically sensitive technique, but we found that tissue itself potently inhibits the polymerase chain reaction if not adequately purified, and despite our spiking experiment we may not have abolished sample inhibition. The incorporation of a modified template may have detected this.
This study has confirmed our previously reported prevalence of such DNA in sarcoid samples but had only 6% "false positivity" compared with our lavage study, in which 32% of elderly control patients were positive for M tuberculosis DNA. Our one positive control specimen was lung tissue taken from a carcinoma in a region of apical fibrosis in a patient aged 45 years. This patient may have had asymptomatic M tuberculosis infection in this classic anatomical site, as is well recognised in patients with chronic bronchitis, in whom it may be unmasked by treatment with steroids. Other studies that used similar techniques for diagnostic purposes give a similar genuine false positive rate."3 We attribute our low rate of false positivity to the use of age matched controls.
Other recent research is consistent with ours. Mycobacterial rRNA has been shown to be raised in sarcoid spleens." Other authors have recently cultured sarcoid skin lesions and grown mycobacteria that on sequencing appear to be M avium Spp. 25 Not all studies using molecular techniques have produced evidence for M tuberculosis as the pathogen in sarcoidosis. Bocart et al6 found mycobacterial DNA in only two of 16 15, 4 and the number of patients is increasing by 100 to 120 patients a year, most ofwhom are adults.5 Considerable rises in the number of adult patients are forecast by the year 2000. 6 There have been few studies of adults with cystic fibrosis with respect to employment, education, housing, insurance, and other features of lifestyle, and most such studies have been based on patients attending large clinics, who may be unrepresentative of the total population with the disease. Patients attending the cystic fibrosis clinic in Melbourne were found to have a good outlook with respect to employment and social life,7 and a study at the Brompton Hospital characterising clinical and social features of patients attending its cystic fibrosis clinic found a similarly good outlook. 8 Our study aimed to describe the social and demographic characteristics of adults with cystic fibrosis in the United Kingdom and the medical care they receive and to provide baseline data from which the impact of changes recently introduced into the National Health Service can be assessed.
Subjects and methods

SUBJECTS
All 1052 people with cystic fibrosis aged over 16 who were alive and known to the Association of Cystic Fibrosis Adults UK (ACFA) on 1 July 1990 were studied. Adults with cystic fibrosis become known to ACFA by transfer from the Cystic Fibrosis Research Trust's mailing list when they reach the age of 18, or by direct referral. Many paediatricians inform the research trust of new patients with cystic fibrosis, with their family's consent, on diagnosis. ACFA membership is biased towards patients attending larger treatment centres where there is awareness of the cystic fibrosis trust, but it contains a substantial proportion of patients who would not be included in a study based on large clinics.
